<?xml version="1.0" encoding="iso-8859-1" ?>
<PASBIO>
    <framesest>
        <predicate lemma="generate">
            <roleset id="generate.01" name="" wordnet="1">
                <roles>
                    <role n="0" descr="agent, causer&#x09;&#x09;//gene, process//&#x0A;" />
                    <role n="1" descr="thing created&#x09;&#x09;&#x0A;" />
                </roles>
                <example src="MEDLINE" no="1">
                    <text>Prnd generates major transcripts of 1.7 and 2.7 kb as well as some unusual chimeric transcripts generated by intergenic splicing with Prnp.</text>
                    <arg n="0">Prnd</arg>
                    <arg n="1">major transcripts of 1.7 and 2.7 kb</arg>
                </example>
                <example src="MEDLINE" no="2">
                    <text>Prnd generates major transcripts of 1.7 and 2.7 kb as well as some unusual chimeric transcripts generated by intergenic splicing with Prnp.</text>
                    <arg n="0">intergenic splicing with Prnp</arg>
                    <arg n="1">some unusual chimeric transcripts</arg>
                </example>
                <example src="MEDLINE" no="3">
                    <text>A transcription start site is located approximately 4 kilobases 5 to the translation codon, and an RNA splice of 3863 bases occurs in the 5-untranslated region to generate mature HeLa cell mRNA.</text>
                    <arg n="0">an RNA splice of 3863 bases occurs in the 5-untranslated region</arg>
                    <arg n="1">mature HeLa cell mRNA</arg>
                </example>
                <example src="MEDLINE" no="4">
                    <text>The TBC method was optimized to generate sequential overlapping fragments ( approximately 0.4-0.5 kb ) for each of the gene sequences, and simultaneous and sequential combinations of overlapping fragments were tested for their ability to be assembled under an array of PCR conditions.</text>
                    <arg n="0">The TBC method</arg>
                    <arg n="1">sequential overlapping fragments</arg>
                </example>
                <example src="MEDLINE" no="5">
                    <text>The bidentate RNase III Dicer cleaves microRNA precursors to generate the 21-23 nt long mature RNAs.</text>
                    <arg n="0">The bidentate RNase III Dicer</arg>
                    <arg n="1">the 21-23 nt long mature RNAs</arg>
                </example>
                <example src="MEDLINE" no="6">
                    <text>In the absence of L-arginine, nNOS has been shown to generate superoxide (O(2)-).</text>
                    <arg n="0">nNOS</arg>
                    <arg n="1">superoxide</arg>
                </example>
                <example src="MEDLINE" no="7">
                    <text>Human leukocyte antigen (HLA)-G molecules are generated by an alternative splicing of the primary transcript of the gene and display specialized function in regulating the immune response.</text>
                    <arg n="0">an alternative splicing of the primary transcript of the gene</arg>
                    <arg n="1">Human leukocyte antigen (HLA)-G molecules</arg>
                </example>
                <example src="MEDLINE" no="8">
                    <text>Abeta peptides are generated from proteolysis of the amyloid precursor proteins (APP) by beta- and gamma-secretases.</text>
                    <arg n="0">proteolysis of the amyloid precursor proteins (APP)</arg>
                    <arg n="1">Abeta peptides</arg>
                </example>
                <example src="EMBO" no="1">
                    <text>In addition, there was an apparent absence of lower molecular weight fragments as evidence of degradation, although again the relatively small fraction involved and the possibility that degradation does not generate specific fragments or occurs rapidly precludes any definitive conclusions.</text>
                    <arg n="0">degradation</arg>
                    <arg n="1">specific fragments</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="EMBO" no="2">
                    <text>The DNA-binding mutant (Stat5aEE-AA) of Stat5a was generated by mutating amino acids EE (437 and 438) to AA.FLAG epitope was added to the C-terminus of Stat5aEE-AA.</text>
                    <arg n="0">mutating amino acids EE (437 and 438) to AA</arg>
                    <arg n="1">The DNA-binding mutant (Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="EMBO" no="3">
                    <text>To analyse specifically protein expression of FHL2 in human tissues we generated a monoclonal antibody against FHL2.</text>
                    <arg n="0">we</arg>
                    <arg n="1">a monoclonal antibody against FHL2</arg>
                </example>
                <example src="EMBO" no="4">
                    <text>Although no crystal structure of the AR is available to date, one might speculate that L723 in H3 is either directly involved in the AR-FHL2 interaction or, alternatively, is essential for generating the correct three-dimensional interaction surface.</text>
                    <arg n="0">L723 in H3</arg>
                    <arg n="1">the correct three-dimensional interaction surface</arg>
                </example>
                <example src="EMBO" no="5">
                    <text>In addition, the AR N-terminus is required to generate a functional interaction surface, since its deletion abolishes FHL2 binding.</text>
                    <arg n="0">the AR N-terminus</arg>
                    <arg n="1">a functional interaction surface</arg>
                </example>
            </roleset>
        </predicate>
    </framesest>
</PASBIO>
